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The mutation detections of KRAS and BRAF genes are of significant importance to predict the responses to anti-cancer therapy 
and develop new drugs. In this paper, we developed a multi-step fluorescence resonance energy transfer (FRET) assay for multi-
plex detection of KRAS and BRAF mutations using cationic conjugated polymers (CCP). The newly established detection system 
could detect as low as 2% mutant DNAs in DNA admixtures. By triggering the emission intensity change of CCP and the dyes 
labeled in the DNA, four possible statuses (three mutations and one wildtype) can be differentiated in one extension reaction. The 
detection efficiency of this new method in clinical molecular diagnosis was validated by determining KRAS and BRAF mutations 
of 51 formalin-fixed paraffin-embedded (FFPE) ovary tissue samples. Furthermore, the result of the CCP-based multi-step FRET 
assay can be directly visualized under UV light so that no expensive instruments and technical expertise are needed. Thus, the 
assay provides a sensitive, reliable, cost-effective and simple method for the detection of disease-related gene mutations.  
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In the era of personalized medicine, understanding the mu-
tation profile of individual tumors is useful for conducting 
anti-cancer therapy. In the past few years, mutations in 
KRAS and BRAF genes have been discovered in many dif-
ferent human cancers [1,2]. Mutation detection in these 
genes has shown good results in predicting response to an-
ti-EGFR therapy in patients with metastatic colorectal can-
cer (CRC) [3–6]. Studies are underway to figure out the 
roles of KRAS and BRAF mutations as predictive bi-
omarkers and drug targets in other cancers therapy [2,7–9]. 
Therefore, it is of significant importance to develop effec-
tive techniques for the detection of KRAS and BRAF muta-
tions that can predict the response to cancer therapy as well 
as develop new drugs. 
Currently, various methods for KRAS and BRAF muta-
tion detection have been reported, such as single strand 
conformation polymorphism analysis (SSCP) [10], high- 
resolution melting analysis (HRMA) [11], direct sequencing 
[10,12], real-time quantitative-PCR (RQ-PCR) method 
[13–15], and SNaPshot assay [16,17]. SSCP and HRMA are 
pre-screening approaches that demand subsequent sequence 
verification of potential mutations, leading to the increased 
time and cost. Direct sequencing is expensive and not sensi-
tive enough to detect low abundant mutations. RQ-PCR has 
much higher analytical sensitivity for mutation detection. 
However, the utilization of organic dyes-labeled oligonu-
cleotide probes carries a high cost. Compared to direct se-
quencing and RQ-PCR methods, SNaPshot assay can sim-
ultaneously screen several mutations and reduce the cost of 
assays. Nevertheless, this method still requires expensive 
instruments and technical expertise. Thus, a simple, inex-
pensive, sensitive, and multiplex mutation diagnosis method 
remains to be explored.  
874 Xing B L, et al.   Chin Sci Bull   March (2013) Vol.58 No.8 
Conjugated polymers (CPs) contain a large number of 
repeated absorbing units, and the transfer of excitation en-
ergy along the whole backbone of CPs to the dye reporter 
can result in the amplification of fluorescence signals, 
providing an optical platform for developing highly sensi-
tive biological detection methods [18–26]. Recently, taking 
advantage of light-harvesting and signal-amplifying prop-
erty of cationic conjugated polymers (CCP), point mutation 
detection of EGFR based on fluorescence resonance energy 
transfer (FRET) has been developed by our group [27,28]. 
The established assay possesses the advantages of conven-
ience, low cost and high sensitivity. In the present work, we 
developed a CCP-based multi-step FRET assay to detect 
KRAS and BRAF somatic mutations. The newly constructed 
method integrate multiplex PCR with multiplex single base 
extension (SBE) reaction, and the detection of multiple 
hotspot mutations can be simultaneously accomplished in 
one tube. In our established detection system, twelve muta-
tions in KRAS and BRAF genes can be detected by suitable 
SBE primer design. The KRAS and BRAF mutations origi-
nated from practical clinical samples can be sensitively de-
termined by utilizing our CCP-based multi-step FRET assay. 
1  Experimental 
1.1  Materials and apparatus 
CCP was prepared using the procedures described in our 
previous paper [24]. Ex Taq, Taq DNA polymerase, shrimp 
alkaline phosphatase (SAP) and exonuclease I were pur-
chased from TaKaRa Biotechnology Co., Ltd (Dalian, Chi-
na). Inorganic pyrophosphatase (yeast) was from New Eng-
land Biolabs (Beijing) Ltd. The dATP labeled with a texas 
red (dATP-TR), dCTP labeled with a fluorescein (dCTP-Fl) 
and dUTP labeled with a fluorescein (dUTP-Fl) were ob-
tained from Perkin Elmer. PAGE-purified DNAs were syn-
thesized by Shanghai Sangon Biological Engineering 
Technology & Services Co., Ltd. QIAmp DNA kit was 
purchased from QIAGEN (Beijing). All PCR and SBE reac-
tions were carried out in a Bio-Rad Mycycler thermocycler. 
Fluorescence spectra were measured with a Hitachi F-4500 
fluorimeter equipped with a Xenon lamp excitation source. 
All photographs were taken with a Canon EOS 550D digital 
camera in a WD-9403F UV Viewing Cabinet (Beijing Liuyi 
Instrument Factory, Bejing, China) under 365 nm UV light 
irradiation. 
1.2  Clinical samples and controls 
Clinical samples were excised from 51 FFPE ovary tissues 
(41 cancer and 10 normal samples). Genomic DNAs 
(gDNA) of these clinical samples were extracted using a 
QIAmp DNA kit according to the manufacturer’s protocol. 
To identify the KRAS and BRAF genes status of these sam-
ples, we sequenced their PCR amplified products using re-
verse primer for KRAS gene and forward primer for BRAF 
gene. Positive controls were mutant DNAs prepared by 
PCR-mediated in vitro mutagenesis [29] and negative control 
was wildtype gDNA sample isolated from 293T cell line. 
1.3  Multiplex PCR amplification 
To amplify KRAS and BRAF genes including the mutation 
sites of interest, multiplex PCR was carried out. The two 
pairs of PCR primers involved were as follows: kras-Fw, 
GCCTGCTGAAAATGACTGAA; kras-Rv, AGAATGGT- 
CCTGCACCAGTA; braf-Fw, CTCTTCATAATGCTTGC- 
TCTG; braf-Rv, TAGTAACTCAGCAGCATCTCA. The  
40 ng of DNA was added to 30 μL of a reaction mixture con-
taining 1×Ex Taq buffer, 2 mmol/L MgCl2, 0.25 mmol/L 
dNTPs, 0.75 unit Ex Taq DNA polymerase, 0.2 μmol/L of 
each primer. Thermal cycler conditions were: 94°C for 2 min, 
45 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 30 s and 
finally 10 min at 72°C. Multiplex PCR products were ana-
lyzed for quality and yield utilizing 2.5% agarose gel elec-
trophoresis. Then 8 μL PCR products were taken to be treated 
with 1 unit of SAP, 10 units of exonuclease I and 0.05 unit of 
pyrophosphatase at 37°C for 1 h to remove excess primers, 
dNTPs, and pyrophosphate generated in PCR. 
1.4  Multiplex SBE reactions 
Multiplex SBE reactions were conducted in a total volume 
of 15 μL containing 1×Taq buffer, 2 μmol/L dATP-TR and 
dUTP-Fl, 1 μmol/L of each SBE primer (Table S1), 1.5 unit 
Taq DNA polymerase, and 1.5 μL exonuclease/SAP/pyro- 
phosphatase-treated multiplex PCR products. Extension 
reactions were ran in a thermal cycler and the conditions 
were 94°C for 2 min, followed by 60 cycles of 94°C for  
30 s and 60°C for 30 s. To degrade unreacted dye-dNTPs, 
each extension products were treated with 1 unit of SAP 
before detecting the FRET signals. 
1.5  CCP-based multi-step FRET measurement and 
visual detection 
For fluorescence measurement, 6 μL multiplex SBE products 
were diluted with 586 μL HEPES buffer (25 mmol/L, pH 8.0), 
and then 8 μL CCP (15 μmol/L) was added to the solution. 
The emission spectra were measured in a 3 mL quartz cuvette 
with an excitation wavelength of 380 nm. For visual detection, 
add 24 μL of CCP (15 μmol/L) to the multiplex SBE prod-
ucts from the above step in PCR tubes, mix thoroughly by 
pipetting, and then take photographs in a WD-9403F UV 
Viewing Cabinet under 365 nm UV light irradiation. 
2  Results and discussion 
In our multi-step FRET assay, cationic poly[(9,9-bis (6′-N, 
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N,N-trimethylammonium)hexyl) fluorenylene phenylene] 
(CCP, see Scheme 1 for chemical structure), fluorescein 
labeled dUTP and Tex Red labeled dATP were used. 
Among them, CCP acts as the donor for fluorescein and Tex 
Red, fluorescein acts as the acceptor for CCP and the donor 
for Tex Red to satisfy the overlap integral requirement for 
FRET. The overall detection strategy for the KRAS and 
BRAF mutations is illustrated in Scheme 1. Firstly, the mul-
tiplex PCR products were amplified from KRAS and BRAF 
genes by two pairs of PCR primers (kras-Fw, kras-Rv, 
braf-Fw and braf-Rv), which contain the mutation sites of 
interest. Secondly, two mutation sites in the amplified DNA 
fragments were simultaneously detected using SBE primers 
(1799T>C and 35G>T) as probes. The 3′-terminal base of 
1799T>C primer is C that is complementary to the 1799T> 
C mutation base but not to that of wildtype; meanwhile, the 
T base at the 3′-terminal of 35G>T primer is complemen-
tary to the 35G>T mutation base rather than the wildtype. 
The dATP-TR, dUTP-Fl, and Taq DNA polymerase are 
used for SBE reactions. In this detection system, there are 
four possible statuses: 1799T>C, 1799T>C/35G>T, 35G>T 
and wildtype. For 1799T>C mutation, only dATP-TR is 
incorporated into the 1799T>C primer, when CCP was 
added, the strong electrostatic interactions between nega-
tively charged DNA and cationic CCP bring them close to 
each other and efficient FRET from CCP to TR occurs upon 
exciting CCP with 380 nm. Similarly, for 35G>T mutation, 
only dUTP-Fl can be incorporated into 35G>T primer, 
leading to efficient FRET from CCP to Fl. For the case of 
1799T>C/35G>T mutations, dATP-TR and dUTP-Fl are 
respectively incorporated into the 1799T>C and 35G>T 
primers, leading to multi-step FRET (CCP→Fl, CCP→TR 
and Fl→TR). For wildtype status, the 3′-terminal bases of 
both 1799T>C and 35G>T are not complementary to the 
wildtype targets, thus the base extension reactions cannot be 
performed. As a result, upon addition of CCP, weak elec-
trostatic interactions between dATP-TR, dUTP-Fl and CCP 
can not keep them close enough, resulting in inefficient 
FRET from CCP to TR and Fl. Therefore, by triggering the 
change of emission intensity or the shift in emission color of 
assay solution, four possible statuses (three mutations and 
one wildtype) can be differentiated in one extension reac-
tion. 
Figure 1(a) shows the emission spectra of SBE products 
upon addition of CCP with the excitation wavelength of 380 
nm, and Figure 1(b) shows the corresponding image of SBE 
products mixed with CCP in PCR tubes under 365 nm UV 
light irradiation. For 1799T>C mutation, efficient FRET 
from CCP to TR led to a significant increase of TR emis-
sion at 613 nm, and the solution exhibited a red color. For 
35G>T mutation, an evident emission of Fl was observed at 
528 nm and the solution emitted a yellow-green color that 
composed of green emission of Fl and the bluish violet 
background. For both 1799T>C and 35G>T mutations, 
emissions of TR and Fl were demonstrated and the solution 
exhibited an orange-red color. For the wildtype, a little TR 
and Fl fluorescence signals were observed and the solution 
displayed a bluish violet color, indicating that a weak non-
specific SBE reaction occurred, but these signals were much 
lower than that of specific SBE reaction. By triggering the 
change of emission intensity or emission color of assay so-
lutions, three kinds of mutation status were clearly distin-
guished from the wildtype sample. 
To assess the sensitivity and reproducibility of our detec-
tion system, we mixed mutant DNA with wildtype DNA in 
various proportions. The emission spectra of a series of ex-
tension products were measured upon adding CCP. All of 
the measurements were repeated three times. As demon-
strated in Figure 2, for 1799T>C or 35G>T mutation, as the 
proportion of mutant target in the test sample increases, the 
emission intensity of TR or Fl increases and that of CCP 
decreases. For 1799T>C/35G>T mutation, the emission 
intensity of TR and Fl increases simultaneously and that of 
CCP decreases when 1799T>C/35G>T mutation proportion 
increases in the samples. By observing the change of emis-
sion intensity, 2%–5% level of detection for 1799T>C, 
1799T>C/35G>T and 35G>T was achieved. In order to 
make test results more intuitive, assay plots with various  
 
 
Scheme 1  Schematic representation of CCP-based multi-step FRET assay for KRAS and BRAF mutation detection and chemical structure of CCP used in 
the assay. 
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Figure 1  (a) Fluorescence spectra of positive (1799T>C, 1799T>C/35G> 
T, 35G>T) and negative controls by mixing SBE products with CCP and 
CCP alone in the HEPES buffer. SBE products were diluted by 100 times 
with HEPES buffer solution (25 mmol/L, pH 8.0) before fluorescence 
measurement. [CCP] = 2×10–7 mol/L in RUs. The excitation wavelength is 
380 nm. (b) The corresponding images of 1799T>C, 1799T>C/35G>T, 
35G>T, and wildtype when SBE products mixed with CCP (15 μmol/L in 
RUs) in PCR tubes under 365 nm UV light irradiation. 
mutation proportions were drawn as functions of FRET ra-
tios (I528 nm/I425 nm as y axis and I613 nm/I425 nm as x axis). As 
revealed in Figure 2(d), the I613 nm/I425 nm and I528 nm/I425 nm 
FRET ratios increase with the increasing of 1799T>C and 
35G>T mutation proportion in the tested samples. As ex-
pected, both I613 nm/I425 nm and I528 nm/I425 nm FRET ratios in-
crease when 1799T>C/35G>T mutation proportion increas-
es in the samples. As shown in the scatter diagram, we were 
able to detect 1799T>C, 1799T>C/35G>T and 35G>T mu-
tations even mutant DNA represented 2% of the total input 
DNA. In addition, the relationship between the FRET ratios 
(I613 nm/I425 nm, I528 nm/I425 nm and (I613 nm+I528 nm)/I425 nm) and 
mutation proportions was investigated. As demonstrated in 
Figure S1, the dynamic range of mutation proportion is 
from 2% to 100%, and all mutation proportions demon-
strated reproducible results. Thus, our CCP-based multiplex 
detection system exhibits excellent sensitivity and repro-
ducibility. 
To investigate the practicality of our CCP-based multi-
plex detection system with clinical samples, we assayed the 
genomic DNAs extracted from 51 FFPE ovary tissues (41 
cancer and 10 normal samples) to determine the presence of 
KRAS and BRAF mutations. The CCP-based multi-step 
FRET assay was designed to detect and differentiate twelve 




Figure 2  Emission spectra from solutions containing CCP and extension products with various mutation proportions. (a) 1799T>C, (b) 35G>T, (c) 
1799T>C/35G>T, (d) assay plots for 1799T>C, 1799T>C/35G>T and 35G>T with various mutation proportions as functions of FRET ratios. 
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Figure 3  Scatter diagram of mutation status from 51 ovary samples using 
FRET ratios (I613 nm/I425 nm) as x axis and FRET ratios (I528 nm/I425 nm) as y 
axis. The cutoff values of I613 nm/I425 nm and I528 nm/I425 nm ratios were (a) 0.19 
and 0.16 for 1799T>C/35G>T probe group, (b) 0.21 and 0.14 for 1799T> 
G/35G>C probe group, respectively. 
codons 12 and 13 of the KRAS gene and three mutations in 
codon 600 of the BRAF gene (Table S2). Twelve SBE pri-
mers were divided into six probe groups to detect the twelve 
mutations (Table S1). Fluorescence spectra using the other 
five probe groups as SBE primers (Figure S2) were con-
sistent with those using p1799T>C/p35G>T probe group 
that was demonstrated in Figure 1. Cutoff values were es-
tablished as the mean +3SD with I613 nm/I425 nm or I528 nm/I425 
nm ratio values of negative control reactions. Only the sam-
ples with readout above these cutoff values were considered 
as positive signals. As presented in FRET ratio scatter dia-
gram in Figure 3, four samples with KRAS mutation were 
identified in 41 ovarian cancer samples by 1799T>C/35G>T 
and 1799T>G/35G>C probe groups. No mutations were 
detected by the other four probe groups (Figure S3). Our 
method can easily differentiate mutation statuses of samples. 
As indicated in Figure 3, of the ovarian cancer samples pos-
itive for KRAS mutations, three samples carried a 35G>T 
mutation and one sample carried a 35G>C mutation. The 
incidence (10%) of KRAS mutations in ovarian cancer sam-
ples was consistent with COSMIC Database (Catalogue Of 
Somatic Mutations In Cancer Database). No BRAF muta-
tions were identified in 41 ovarian cancer samples. Accord-
ing to COSMIC Database, the incidence of BRAF mutations 
is 3% in ovarian cancer. The low incidence may explain the 
absence of BRAF mutations in our assay. Furthermore, no 
mutations were detected in 10 normal ovary samples. DNA 
sequencing analysis was performed to confirm the presence 
of mutations. As revealed in Figure S4, four mutations were 
consistent with the results obtained from the CCP-based 
multiplex detection system. This supports the tentative con-
clusion that our CCP-based multi-step FRET assay is a val-
id approach to efficiently detect somatic mutations in clini-
cal samples. 
3  Conclusions 
In summary, we have demonstrated CCP-based multi-step 
FRET assay for multiplex detection of KRAS and BRAF 
mutations. Compared to the methods reported previously, 
our assay possesses the following several unique features. 
Firstly, taking advantage of light-harvesting and light-am- 
plifying effect of CCP, high sensitivity was obtained. The 
new detection system could detect even as low as 2% muta-
tion of total DNA. The application of this method in clinical 
molecular diagnosis was validated by determining KRAS 
and BRAF mutations in 51 FFPE ovary tissues. Secondly, 
by triggering the emission intensity change of assay solution, 
four possible statuses (three mutations and one wildtype) 
can be differentiated in one extension reaction, which 
streamlined workflow, and saved diagnostic time and DNA 
input. More importantly, the detection can be visualized 
under UV light so that no expensive instruments and tech-
nical expertise are needed. Our method is sensitive, reliable, 
cost-effective and simple for KRAS and BRAF mutation 
detection. Therefore, with the era of personalized medicine 
coming, it is believed that the CCP-based multi-step FRET 
assay has greatly potential application in clinical diagnosis. 
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Figure S1  Relationship between the FRET ratios (I613 nm/I425 nm, I528 nm/I425 nm and (I528 nm+I613 nm)/I425 nm) and mutation percentage. (a) 1799T>C, (b) 35G> 
T, (c) 1799T>C/35G>T. The maximum RSD was 8.3%. 
Figure S2  (a) Fluorescence spectra and corresponding images of assay solutions using the other five probe groups as SBE primers. (a) 1799T> 
A/p35G>A, (b) 1799T>G/35G>C, (c) 34G>A/38G>A, (d) 34G>C/38G>C, (e) 34G>T/38G>T. The experiment condition is the same as described in the 
Figure 1 in the text. 
Figure S3   Scatter diagram of mutation status from 51 ovary samples using the other four probe groups as SBE primers. (a) 1799T>A/35G>A, (b) 
34G>A/38G>A, (c) 34G>C/38G>C, (d) 34G>T/38G>T. 
Figure S4  Sequencing results of mutant samples. Reverse primer was used as sequencing primer. 
Table S1  SBE probe groups used in CCP-based multi-step FRET assay  
Table S2  Twelve mutations in KRAS and BRAF genes 
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